DE-Flensburg-MALTESER
Welcome,         Profile    Billing    Logout  
 1 Trial 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Basara, Nadezda
NCT03897127: Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics

Recruiting
3
882
Europe
Cytarabine, Daunorubicin, CPX-351
University of Ulm, Jazz Pharmaceuticals
Acute Myeloid Leukemia
06/27
06/27
HOVON 156 AML, NCT04027309 / 2018-000624-33: A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

Active, not recruiting
3
777
Europe, RoW
Gilteritinib, ASP2215, Midostaurin, Rydapt
Stichting Hemato-Oncologie voor Volwassenen Nederland, Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG), Astellas Pharma Global Development, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2
10/25
06/33
TARC, NCT04177602: Evaluating Trifluridine/Tipiracil Based Chemoradiation in Locally Advanced Rectal Cancer - The Phase I/II Trial

Terminated
1/2
10
Europe
Trifluridine/tipiracil chemoradiation, Capecitabine based chemoradiation
Universitätsklinikum Hamburg-Eppendorf, Clinical Trial Center North (CTC North GmbH & Co. KG), Servier Affaires Médicales
Locally Advanced Rectal Cancer
09/22
09/22
AMLSG BiO, NCT01252485: Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - the Biology and Outcome (BiO)-Project

Recruiting
N/A
50000
Europe
University of Ulm
Acute Myeloid Leukemia (AML), MDS/AML
12/44
12/44
Krackhardt, Angela
NCT03897127: Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics

Recruiting
3
882
Europe
Cytarabine, Daunorubicin, CPX-351
University of Ulm, Jazz Pharmaceuticals
Acute Myeloid Leukemia
06/27
06/27
NCT06652438: Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

Recruiting
3
415
Europe
Revumenib, Placebo
Stichting Hemato-Oncologie voor Volwassenen Nederland, German-Austrian Acute Myeloid Leukemia Study Group, United Kingdom AML Research Network
Acute Myeloid Leukemia, Adult
12/29
07/31
AMLSG BiO, NCT01252485: Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - the Biology and Outcome (BiO)-Project

Recruiting
N/A
50000
Europe
University of Ulm
Acute Myeloid Leukemia (AML), MDS/AML
12/44
12/44
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Basara, Nadezda
NCT03897127: Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics

Recruiting
3
882
Europe
Cytarabine, Daunorubicin, CPX-351
University of Ulm, Jazz Pharmaceuticals
Acute Myeloid Leukemia
06/27
06/27
HOVON 156 AML, NCT04027309 / 2018-000624-33: A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

Active, not recruiting
3
777
Europe, RoW
Gilteritinib, ASP2215, Midostaurin, Rydapt
Stichting Hemato-Oncologie voor Volwassenen Nederland, Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG), Astellas Pharma Global Development, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2
10/25
06/33
TARC, NCT04177602: Evaluating Trifluridine/Tipiracil Based Chemoradiation in Locally Advanced Rectal Cancer - The Phase I/II Trial

Terminated
1/2
10
Europe
Trifluridine/tipiracil chemoradiation, Capecitabine based chemoradiation
Universitätsklinikum Hamburg-Eppendorf, Clinical Trial Center North (CTC North GmbH & Co. KG), Servier Affaires Médicales
Locally Advanced Rectal Cancer
09/22
09/22
AMLSG BiO, NCT01252485: Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - the Biology and Outcome (BiO)-Project

Recruiting
N/A
50000
Europe
University of Ulm
Acute Myeloid Leukemia (AML), MDS/AML
12/44
12/44
Krackhardt, Angela
NCT03897127: Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics

Recruiting
3
882
Europe
Cytarabine, Daunorubicin, CPX-351
University of Ulm, Jazz Pharmaceuticals
Acute Myeloid Leukemia
06/27
06/27
NCT06652438: Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

Recruiting
3
415
Europe
Revumenib, Placebo
Stichting Hemato-Oncologie voor Volwassenen Nederland, German-Austrian Acute Myeloid Leukemia Study Group, United Kingdom AML Research Network
Acute Myeloid Leukemia, Adult
12/29
07/31
AMLSG BiO, NCT01252485: Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - the Biology and Outcome (BiO)-Project

Recruiting
N/A
50000
Europe
University of Ulm
Acute Myeloid Leukemia (AML), MDS/AML
12/44
12/44

Download Options